Consensus Aquestive Therapeutics, Inc.

Stocks

AQST

US03843E1047

Pharmaceuticals

Real-time Estimate Cboe BZX 01:41:41 30/10/26 am AEDT			5-day change	1st Jan Change
4.235 ^USD	+0.12%		+3.27%	-33.98%

15/10	Aquestive Therapeutics, Inc. Announces FDA Acceptance Of Anaphylm NDA Resubmission And PDUFA Goal Date Of March 16, 2027	CI
15/10	Aquestive Therapeutics Says FDA Accepts Resubmitted Filing for Anaphylm in Severe Allergy	MT

Evolution of the Average Target: Aquestive Therapeutics, Inc.

Evolution of the Target Price: Aquestive Therapeutics, Inc.

Changes in Analyst Recommendations: Aquestive Therapeutics, Inc.

b0b450ac32409dc7a0.cf4UhNhPNabPlAOjDPgSy54fwaqUdAMyPk2mkUth8uo.EJ1s_Lx3f_aJzGrLWIh8gORdo_n9OEZ4bGCVxA8Lw7kXhyTD7xdz4ZugTg~83b87fbe39acc45b250128699acec3b8

Analysts' recommendations: Aquestive Therapeutics, Inc.

10/01	Top Midday Decliners	MT
05/11	Aquestive Therapeutics, Inc. Announces Executive Appointments	CI
08/09/25	Oppenheimer Adjusts Aquestive Therapeutics Price Target to $8 From $7, Maintains Outperform Rating	MT
17/12/24	Cantor Fitzgerald Initiates Aquestive Therapeutics at Overweight With $17 Price Target	MT
10/05/24	Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	MT
11/04/24	Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	MT
28/03/24	Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	MT
19/03/24	H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	MT
16/03/24	JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	MT
12/03/24	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $7 From $6, Maintains Buy Rating	MT
07/03/24	Wedbush Lifts Aquestive Therapeutics' PT to $9 From $4 After Model Adjustments, Keeps Outperform Rating	MT
09/11/23	HC Wainwright Raises Price Target on Aquestive Therapeutics to $6 From $5, Maintains Buy Rating	MT
10/08/23	Wedbush Lifts Aquestive Therapeutics' Price Target to $4 From $3 Due to Decreased Share Count, Keeps Outperform Rating	MT
03/07/23	Wedbush Trims Aquestive Therapeutics' PT to $3 From $4, Pushes US, EU Launch Estimates for Anaphylm/Anaphylaxis; Keeps Outperform Rating	MT
10/03/23	Wedbush Upgrades Aquestive Therapeutics to Outperform Rating From Neutral, Adjusts Price Target to $4 From $3	MT
31/01/23	Wedbush Downgrades Aquestive Therapeutics to Neutral From Outperform, Notes Limited Cash Runway; Trims Price Target to $3 From $4	MT
05/11/22	Alliance Global Partners Adjusts Price Target on Aquestive Therapeutics to $7 From $10, Maintains Buy Rating	MT
08/09/22	Oppenheimer Initiates Coverage on Aquestive Therapeutics With Outperform Rating, $8.50 Price Target	MT
06/09/22	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $6, Reiterates Buy Rating	MT
02/09/22	BMO Capital Adjusts Aquestive Therapeutics' Price Target to $6 from $9, Maintains Outperform Rating	MT
30/08/22	Alliance Global Initiates Aquestive Therapeutics at Buy Rating With $10 Price Target	MT
04/08/22	Wedbush Adjusts Price Target on Aquestive Therapeutics to $4 From $8 on Potential Share Count Increase; Outperform Rating Kept	MT
21/06/22	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $8, Reiterates Buy Rating	MT
31/05/22	HC Wainwright Adjusts Aquestive Therapeutics' Price Target to $8 From $14, Keeps Buy Rating	MT
10/03/22	Wedbush Adjusts Aquestive Therapeutics' Price Target to $8 From $26, Removes Libervant From Pipeline Valuation; Outperform Rating Kept	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AQUESTIVE THERAPEUTICS, INC.					+120.65%
	ELI LILLY AND COMPANY					+3.53%
	JOHNSON & JOHNSON					+3.09%
	ABBVIE INC.					-0.98%
	ROCHE HOLDING AG					-2.95%
	MERCK & CO., INC.					+13.36%
	NOVARTIS AG					-1.36%
	ASTRAZENECA PLC					+23.73%
	AMGEN INC.					-12.06%
	GILEAD SCIENCES, INC.					+0.62%
	Average					+14.76%
	Weighted average by Cap.					+3.02%